Climb Bio, Inc. CLYM US — Net Income Loss
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Climb Bio, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Climb Bio, Inc.'s us — net income loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Climb Bio, Inc.'s US — net income loss?
- Climb Bio, Inc. (CLYM) reported US — net income loss of -$14.89M in Q4 2025.
- How has Climb Bio, Inc.'s US — net income loss changed year-over-year?
- Climb Bio, Inc.'s US — net income loss increased by 11.3% year-over-year, from -$16.78M to -$14.89M.
- What is the long-term trend for Climb Bio, Inc.'s US — net income loss?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s US — net income loss has grown at a 45.5% compound annual growth rate (CAGR), from -$13.31M to -$59.58M.
- What does US — net income loss mean?
- This metric represents the net profit or loss generated specifically by the company's operations within the United States geographic segment. It reflects the bottom-line financial performance after accounting for all segment-specific revenues, research and development expenditures, and operating costs. Monitoring this figure helps investors assess the financial sustainability and resource consumption of the company's primary domestic clinical development activities.